| 苏慎勇,洪 丹,安 琳,王坤杰,陈 渊,王志宇,魏亚宁,肖 恒.血清TAP、TFF3与晚期胃癌患者含奥沙利铂化疗方案敏感性和预后的关系[J].现代生物医学进展英文版,2023,(14):2766-2769. |
| 血清TAP、TFF3与晚期胃癌患者含奥沙利铂化疗方案敏感性和预后的关系 |
| Relationship between Serum TAP, TFF3 and Sensitivity of Containing Oxaliplatin Chemotherapy Regimen and Prognosis in Patients with Advanced Gastric Cancer |
| Received:February 07, 2023 Revised:February 25, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.14.032 |
| 中文关键词: 晚期胃癌 奥沙利铂 化疗 TAP TFF3 敏感性 预后 |
| 英文关键词: Advanced gastric cancer Oxaliplatin Chemotherapy TAP TFF3 Sensitivity Prognosis |
| 基金项目:保定市科技计划自筹经费项目（2241ZF338）；河北省医学科学研究重点课题计划项目（20170187） |
|
| Hits: 570 |
| Download times: 389 |
| 中文摘要: |
| 摘要 目的：探讨血清肿瘤异常蛋白（TAP）、三叶因子3（TFF3）与晚期胃癌患者应用含奥沙利铂化疗方案敏感性和预后的关系。方法：选择2017年1月至2020年1月河北大学附属医院收治的115例晚期胃癌患者，所有患者接受含奥沙利铂化疗方案治疗，根据疗效分为敏感组（47例）和耐药组（68例）。化疗前检测血清TAP、TFF3水平，受试者工作特征（ROC）曲线分析TAP、TFF3预测晚期胃癌患者接受含奥沙利铂化疗疗效的价值。治疗后随访，Wilcoxon检验不同血清TAP、TFF3表达下晚期胃癌患者中位OS时间差异。结果：耐药组血清TAP、TFF3水平高于敏感组（P＜0.05）。TAP、TFF3预测晚期胃癌患者含奥沙利铂化疗耐药的曲线下面积分别为0.717、0.690，联合TAP和TFF3预测晚期胃癌患者含奥沙利铂化疗耐药的曲线下面积为0.801，高于单独TAP、TFF3单独检测。随访期间失访2例，死亡54例，高水平TAP、高水平TFF3晚期胃癌患者中位OS时间短于低水平TAP、低水平TFF3晚期胃癌患者（P＜0.05）。结论：对含奥沙利铂化疗耐药的晚期胃癌患者血清TAP、TFF3水平显著增高，高水平TAP、TFF3晚期胃癌患者中位OS时间较短，联合检测血清TAP和TFF3可预测晚期胃癌患者化疗反应性和预后。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the relationship between serum tumor abnormal protein (TAP), trefoil factor 3 (TFF3) and the sensitivity and prognosis of containing oxaliplatin chemotherapy regimen in patients with advanced gastric cancer. Methods: 115 patients with advanced gastric cancer who were admitted to Affiliated Hospital of Hebei University from January 2017 to January 2020 were selected. All patients received containing oxaliplatin chemotherapy regimen treatment, and they were divided into sensitive group (47 cases) and drug-resistant group(68 cases) according to the efficacy. Serum TAP and TFF3 levels were detected before chemotherapy, and the value of TAP and TFF3 in predicting the efficacy of oxaliplatin chemotherapy in patients with advanced gastric cancer was analyzed by receiver operating characteristic(ROC) curve. After treatment of follow-up, Wilcoxon analysis was used to analyze the difference in the median OS survival time of patients with advanced gastric cancer with different serum TAP and TFF3 expression. Results: Serum TAP and TFF3 levels in the drug-resistant group were higher than those in the sensitive group (P＜0.05). TAP and TFF3 predicted the area under curve of containing oxaliplatin chemotherapy resistance of patients with advanced gastric cancer were 0.717 and 0.690, respectively, combined TAP and TFF3 predicted the area under curve of containing oxaliplatin chemotherapy resistance of patients with advanced gastric cancer was 0.801, which was higher than TAP and TFF3 alone detection. During follow-up, 2 cases were lost to follow-up, and 54 cases died, the median OS survival time of patients with high level of TAP and high level of TFF3 and advanced gastric cancer were lower than those of patients with low level of TAP and low level of TFF3 and advanced gastric cancer (P＜0.05). Conclusion: Serum TAP and TFF3 levels were significantly higher in advanced gastric cancer patients who were resistant to containing oxaliplatin chemotherapy, and high levels of TAP and TFF3 were associated with a shorter median OS survival time in advanced gastric cancer patients, and the combined detection of serum TAP and TFF3 may predict chemotherapeutic responsiveness and prognosis in advanced gastric cancer patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
